Minerva Neurosciences (NERV) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Minerva Neurosciences is the larger company by market cap ($153.7 million vs $141.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | RNA |
|---|---|---|
| Share price | $3.22 | $8.26 |
| Market cap | $153.75M | $141.29M |
| 1-day change | -1.53% | +4.16% |
| YTD return | -19.90% | — |
| 1-year return | +13.78% | — |
| 5-year return | -70.19% | — |
| EPS (TTM) | $-35.62 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.46 | $16.77 |
| 52-week low | $2.24 | $7.63 |
| Distance from 52-week high | -74.16% | -50.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +220.81% | +202.66% |
| Average volume | 183.63K | 259.35K |
| Shares outstanding | 47.75M | 17.11M |
| Employees | 7 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
NERV vs RNA FAQ
Which is bigger, Minerva Neurosciences or Atrium Therapeutics?
Minerva Neurosciences (NERV) is larger, with a market capitalization of $153.75M compared with $141.29M for Atrium Therapeutics (RNA).
Are Minerva Neurosciences and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.